Can Vraylar (cariprazine) cause elevated alanine aminotransferase (ALT) levels?

Can Vraylar Cause ALT Elevation?

Yes, Vraylar (cariprazine) can cause elevated ALT levels, though this occurs infrequently and is typically mild to moderate in severity.

Evidence from FDA Drug Label

The FDA prescribing information for Vraylar does not list hepatotoxicity or ALT elevation as a prominent adverse effect in the main warnings and precautions sections 11. However, clinical trial data provides relevant information:

Documented Incidence in Clinical Trials

In a pediatric study of cariprazine in patients with autism spectrum disorder, increased alanine aminotransferase was among the most frequent treatment-emergent adverse events (TEAEs) 2. Importantly:

• All ALT elevations were mild or moderate in severity
• No patients discontinued treatment due to ALT elevations
• The increases were not considered clinically meaningful

This represents the most direct evidence linking Vraylar to ALT elevation, though the frequency and clinical significance appear limited.

Clinical Context and Interpretation

When to Suspect Vraylar as the Cause

Consider cariprazine as a potential cause of ALT elevation when:

• Timing: ALT elevation occurs after initiating Vraylar (note: adverse reactions may appear several weeks after initiation due to drug accumulation) 1
• Magnitude: Elevations are typically mild (1-3× ULN based on available data)
• Pattern: Hepatocellular pattern (ALT predominant) rather than cholestatic
• Exclusion: Other common causes have been ruled out (viral hepatitis, alcohol, other medications, metabolic syndrome)

Monitoring Recommendations

While Vraylar's FDA label does not mandate routine liver function monitoring 11, prudent clinical practice suggests:

• Baseline ALT before starting treatment
• Consider repeat testing at 4-8 weeks (when steady-state is achieved and late-occurring adverse reactions may manifest)
• Monitor if patient develops symptoms suggestive of hepatotoxicity (fatigue, nausea, right upper quadrant pain)

Management Thresholds

Using established DILI management principles from guidelines 3:

For patients with normal baseline ALT:

• ALT ≥5× ULN: Repeat testing in 2-5 days, evaluate alternative causes
• ALT ≥8× ULN: Interrupt Vraylar, close monitoring, restart only if alternative etiology identified
• ALT ≥3× ULN + bilirubin ≥2× ULN: Interrupt Vraylar immediately (Hy's Law threshold)

For patients with elevated baseline ALT:

• ALT ≥3× baseline or ≥300 U/L: Repeat testing, evaluate causes
• ALT ≥5× baseline or ≥500 U/L: Interrupt Vraylar

Important Caveats

• Atypical antipsychotics as a class are associated with metabolic changes 1, which can indirectly affect liver enzymes through development of metabolic syndrome and fatty liver disease
• The long half-life of cariprazine and its active metabolites means drug effects persist for weeks after discontinuation 1
• ALT elevations may be multifactorial in psychiatric patients who often have comorbid conditions (obesity, diabetes, substance use) that independently affect liver enzymes

Bottom Line

Vraylar can cause ALT elevation, but this appears to be an uncommon and generally mild adverse effect based on available clinical trial data 2. The drug is not known for significant hepatotoxicity. When ALT elevation occurs in a patient taking Vraylar, apply standard DILI assessment principles 3, but maintain a broad differential diagnosis given the multiple potential contributors to liver enzyme abnormalities in this patient population.